Pfizer to spend $120 million to boost U.S. COVID pill manufacturing
Tweet
Share
E-mail
FILE PHOTO: The Pfizer logo is seen at the entrance to Pfizer UK headquarters in Tadworth, Britain, December 2, 2020. REUTERS/Peter Nicholls
(Reuters) - Pfizer Inc said on Monday it would spend $120 million to expand manufacturing of its COVID-19 antiviral treatment at its Michigan plant, as demand ramps up.
Use of the pill, Paxlovid, authorized to treat newly infected, at-risk people to prevent severe illness, has soared recently as infections rise.
Biden administration officials have pushed for the wider use of Paxlovid, which the government distributes for free.
(Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GitLab’s second-quarter revenue jumps 21% as AI demand drives bookings
- Palo Alto Networks’ quarterly profit jumps as AI security demand accelerates
- Citi opens downside catalyst watch on Kroger as Walmart price war intensifies
Create E-mail Alert Related Categories
General News, ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
